Pre-existing immunity and hrHPV status determine immunotherapy response in advanced penile cancer: biomarkers and overall survival in the PERICLES trial.
Certain immune cell markers in penile cancer predict which patients benefit most from immunotherapy, potentially guiding personalized treatment choices.
This PubMed record reports a phase 2 clinical trial on Pre-existing immunity and hrHPV status determine immunotherapy response in advanced penile cancer: biomarkers and overall survival in the PERICLES trial. The authors report that interrogation of the penile cancer immune microenvironment highlights CD8+PD1+ T-cells as candidate biomarkers in relation to clinical benefit from immune checkpoint blockade in advanced PeSCC.
What the study was
- Study design
- Phase 2 clinical trial
- Population
- Human participants or clinical records described in the abstract
- Category
- Treatment Innovation
- Maturity
- Exploratory
- Journal
- Cancer immunology research
Why it surfaced
Phase 2 clinical trial with direct human relevance was scored conservatively from PubMed abstract and citation metadata.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.